[1]中国抗癌协会肿瘤介入学专业委员会,中国抗癌协会肿瘤介入学专业委员会化疗与免疫治疗分委会.改良式经皮肝动脉化疗药盒植入技术中国专家共识（2022版）[J].介入放射学杂志,2022,31(07):633-641.
　Professional Committee of Oncology Intervention,China Anti-Cancer Association,Chinese expert consensus on the modified implantation technique of port-catheter system for percutaneous hepatic arterial infusion chemotherapy（version 2022）[J].journal interventional radiology,2022,31(07):633-641.
点击复制

改良式经皮肝动脉化疗药盒植入技术中国专家共识（2022版）()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
31
期数:
2022年07
页码:
633-641
栏目:
指南与共识
出版日期:
2022-09-03

文章信息/Info

Title:
Chinese expert consensus on the modified implantation technique of port-catheter system for percutaneous hepatic arterial infusion chemotherapy（version 2022）
作者:
中国抗癌协会肿瘤介入学专业委员会; 中国抗癌协会肿瘤介入学专业委员会化疗与免疫治疗分委会
Author(s):
Professional Committee of Oncology Intervention;  China Anti-Cancer Association；
Sub-committee of Chemotherapy and Immunotherapy， Professional Committee of Oncology Intervention， China Anti-Cancer Association
关键词:
【关键词】 改良式经皮肝动脉化疗药盒植入术; 肝动脉灌注化疗; 肝胆系统恶性肿瘤; 专家共识
文献标志码:
A
摘要:
【摘要】 近年来，肝动脉灌注化疗（HAIC）作为介入治疗技术之一，应用于治疗进展期肝胆恶性肿瘤的效果逐渐受到认可。但不同临床中心的HAIC操作技术差别较大，缺乏行业规范，且多数以一次性穿刺留管形式完成。为了满足HAIC需长时间持续灌注、多次反复给药的特点，经皮肝动脉化疗药盒系统比一次性穿刺留管更具优势。改良式经皮肝动脉化疗药盒系统植入术采用管头固定技术、肝内外血流再分布术，具有创伤小、导管移位率低、实现全肝灌注、患者舒适性高、并发症少等优点，已在国内外多个临床中心得以证实。为了更好地规范HAIC治疗技术，通过回顾文献并经临床实践和充分讨论，参与本共识编写专家达成改良式经皮肝动脉化疗药盒植入术标准化操作流程、技术要点、HAIC方案、术后并发症防治、药盒系统维护及相关护理常规等共识。

参考文献/References:

［1］ Konstantinidis IT， Groot Koerkamp B， Do RK， et al. Unresectable intrahepatic cholangiocarcinoma： systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone［J］. Cancer， 2016， 122： 758- 765.
［2］ Dhir M， Jones HL， Shuai Y， et al. Hepatic arterial infusion in combination with modern systemic chemotherapy is associated with improved survival compared with modern systemic chemotherapy alone in patients with isolated unresectable colorectal liver metastases： a case- control study［J］. Ann Surg Oncol， 2017， 24： 150- 158.
［3］ Chan DL， Alzahrani NA， Morris DL， et al. Systematic review and meta- analysis of hepatic arterial infusion chemotherapy as bridging therapy for colorectal liver metastases［J］. Surg Oncol， 2015， 24： 162- 171.
［4］ Wang X， Hu J， Cao G， et al. Phase II study of hepatic arterial infusion chemotherapy with oxaliplatin and 5- fluorouracil for advanced perihilar cholangiocarcinoma［J］. Radiology， 2017， 283： 580- 589.
［5］ Konstantinidis IT， Do RK， Gultekin DH， et al. Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma： a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials［J］. Ann Surg Oncol， 2014， 21： 2675- 2683.
［6］ Zheng K，Zhu X，Fu S， et al. Sorafenib plus hepatic arterial infusion chemotherapy versus sorafenib for hepatocellular carcinoma with major portal vein tumor thrombosis： a randomized trial［J］. Radiology， 2022， 303：455- 464.
［7］ Lyu N， Wang X， Li JB， et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma： a biomolecular exploratory， randomized， phase Ⅲ trial（FOHAIC- 1）［J］. J Clin Oncol， 2022， 40： 468- 480.
［8］ Li QJ， He MK， Chen HW， et al. Hepatic arterial infusion of oxaliplatin， fluorouracil， and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma： a randomized phase Ⅲ trial［J］. J Clin Oncol， 2022， 40： 150- 160.
［9］ He M， Li Q， Zou R， et al. Sorafenib plus hepatic arterial infusion of oxaliplatin， fluorouracil， and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion： a randomized clinical trial［J］. JAMA Oncol， 2019， 5： 953- 960.
［10］ Liu B， Zhu X， Gao S， et al. Safety and efficacy of hepatic arterial infusion chemotherapy with raltitrexed and oxaliplatin post- transarterial chemoembolization for unresectable hepatocellular carcinoma［J］. J Intervent Med， 2019， 2： 91- 96.
［11］ Zhao Y， Lai J， Liang R， et al. Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma［J］. J Intervent Med， 2019， 2： 78- 83.
［12］ 赵东旭，张 磊，姜小庆，等． HAIC是老技术还是新方法——理性看待肝动脉灌注化疗［J］． 介入放射学杂志， 2022， 31：2- 8．
［13］ Yamagami T， Iida S， Kato T， et al. Using n- butyl cyanoacrylate and the fixed- catheter- tip technique in percutaneous implantation of a port- catheter system in patients undergoing repeated hepatic arterial chemotherapy［J］. AJR Am J Roentgenol， 2002， 179： 1611- 1617.
［14］ Mahnken AH， Pereira PL， de Baere T. Interventional oncologic approaches to liver metastases［J］. Radiology， 2013， 266： 407- 430.
［15］ De Baere T， Mariani P. Surgical or percutaneous hepatic artery cannulation for chemotherapy［J］. J Visc Surg， 2014， 151（Suppl 1）： S17- S20.
［16］ Koganemaru M， Abe T， Iwamoto R， et al. Hepatic arterial infusion chemotherapy with a coaxial reservoir system using a non- braided spiral tip microcatheter［J］. Jpn J Radiol， 2012， 30： 10- 17.
［17］ Sinn M，Nicolaou A，Ricke J， et al. Interventionally implanted port catheter systems for hepatic arterial infusion of chemo- therapy in patients with primary liver cancer： a phase Ⅱ- study （NCT00356161）［J］. BMC Gastroenterol， 2013， 13：125.
［18］ Hildebrandt B， Pech M， Nicolaou A， et al. Interventionally implanted port catheter systems for hepatic arterial infusion of chemotherapy in patients with colorectal liver metastases： a phase Ⅱ- study and historical comparison with the surgical approach［J］. BMC cancer 2007， 7：69.
［19］ Deschamps F， Elias D， Goere D， et al. Intra- arterial hepatic chemotherapy： a comparison of percutaneous versus surgical implantation of port- catheters［J］. Cardiovasc Intervent Radiol， 2011， 34： 973- 979.
［20］ 詹迎江，程永德． 锁骨下动脉经皮导管药盒系统植入法的临床应用［J］． 介入放射学杂志， 1998， 7： 211- 213．
［21］ Seki H， Ozaki T， Shiina M. Side- hole catheter placement for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer： long- term treatment and survival benefit［J］. AJR Am J Roentgenol， 2008， 190： 111- 120.
［22］ Hu J， Zhu X， Wang X， et al. Evaluation of percutaneous unilateral trans- femoral implantation of side- hole port- catheter system with coil only fixed- catheter- tip for hepatic arterial infusion chemotherapy［J］. Cancer Imaging， 2019， 19： 15.
［23］ Matsumoto T， Yamagami T， Yoshimatsu R， et al. Hepatic arterial infusion chemotherapy by the fixed- catheter- tip method： retros-pective comparison of percutaneous left subclavian and femoral port- catheter system implantation［J］. AJR Am J Roentgenol， 2014， 202： 211- 215.
［24］ Yamagami T， Yoshimatsu R， Matsumoto T， et al. Evaluation of non- target arterial patency after implantation of hepatic arterial catheter using a modified implantation technique with the fixed catheter tip method［J］. Clin Radiol， 2009， 64： 164- 170.
［25］ Hu J， Bao Q， Cao G， et al. Hepatic arterial infusion chemotherapy using oxaliplatin plus 5- fluorouracil versus transarterial chemoembolization/embolization for the treatment of advanced hepatocellular carcinoma with major portal vein tumor thrombosis［J］. Cardiovasc Intervent Radiol， 2020， 43： 996- 1005.
［26］ Zheng K， Wang X， Cao G， et al. Hepatic arterial infusion chemotherapy with oxaliplatin and 5- fluorouracil for advanced gallbladder cancer［J］. Cardiovasc Intervent Radiol， 2021， 44： 271- 280.
［27］ Arai Y， Takeuchi Y， Inaba Y， et al. Percutaneous catheter placement for hepatic arterial infusion chemotherapy［J］. Tech Vasc Interv Radiol， 2007， 10： 30- 37.
［28］ Guyatt GH， Oxman AD， Vist GE， et al. GRADE： an emerging consensus on rating quality of evidence and strength of recom- mendations［J］. BMJ， 2008， 336： 924- 926.
［29］ Yamagami T， Kato T， Iida S， et al. Efficacy of the left gastric artery as a route for catheterization of the right gastric artery［J］. AJR Am J Roentgenol， 2005， 184： 220- 224.
［30］ Hu J， Cao G， Xu L， et al. Retrograde embolization technique of the right gastric artery during the implantation of port- catheter system for hepatic arterial infusion chemotherapy［J］. J Intervent Med， 2021， 4： 27- 31.
［31］ Wang YJ， Lao IH， Tzeng WS， et al. Hepatic artery infusion catheter implantation without embolization of the gastroduodenal artery in cases of retrograde blood flow［J］. J Vasc Interv Radiol， 2010， 21： 1297- 1300.
［32］ Yamagami T， Kato T， Hirota T， et al. A simplified method for continuous hepatic arterial port- catheter system placement not requiring catheter end- hole occlusion［J］. Acta Radiol， 2006， 47： 775- 779.
［33］ Zhao X， Sun X， Jing J， et al. Safety study of Folfox- HAIC in relieving bed restriction［J］. J Intervent Med ， 2021， 4： 203- 207.
［34］ Key NS， Khorana AA， Kuderer NM， et al. Venous thromboem- bolism prophylaxis and treatment in patients with cancer： ASCO clinical practice guideline update［J］. J Clin Oncol， 2020， 38： 496- 520.
［35］ Murata S， Tajima H， Abe Y， et al. Transcatheter management for multiple liver tumors after hepatic artery obstruction following reservoir placement［J］. Hepatogastroenterology， 2005， 52： 852- 856.
［36］ Yamagami T， Kato T， Iida S， et al. Interventional radiologic treatment for hepatic arterial occlusion after repeated hepatic arterial infusion chemotherapy via implanted port- catheter system［J］. J Vasc Interv Radiol， 2004， 15： 633- 639.
［37］ 康志龙，杨仁杰. 动脉导管药盒系统在肿瘤介入治疗中的应用进展［J］. 临床肿瘤学杂志， 2010， 15：952- 954

相似文献/References:

[1]李晓光,金征宇,潘杰,等.肝动脉化疗或栓塞治疗胰腺神经内分泌肿瘤肝转移的疗效分析[J].介入放射学杂志,2010,(06):442.
　LI Xiaoguang,JIN Zhengyu,PAN Jie,et al.Hepatic transarterial chemoperfusion and chemoembolization for the treatment of liver metastases from pancreatic neuroendocrine tumors：a therapeutic analysis[J].journal interventional radiology,2010,(07):442.
[2]陈伟敏,罗佐权.肝癌肝动脉灌注化疗与静脉输注硫代硫酸钠的“双路”疗法18例报告[J].介入放射学杂志,1992,(01):26.
[3]牛树茂,徐元贞,赵殿有,等.肝动脉灌注化疗后引起带状疱疹样皮疹六例报告[J].介入放射学杂志,1994,(01):54.
[4]秦伟,巫北海.5-FUDR经肝动脉灌注致硬化性胆管炎[J].介入放射学杂志,1996,(01):59.
[5]徐永康,付舒敏,李　丹,等.肝动脉灌注化疗联合系统治疗在原发性肝癌中的研究进展[J].介入放射学杂志,2023,32(01):94.
　XU Yongkang,FU Shumin,LI Dan,et al.Research progress in hepatic arterial infusion chemotherapy combined with systemic therapy for the treatment of primary hepatocellular carcinoma[J].journal interventional radiology,2023,32(07):94.
[6]曹佳伟,李慧婷,徐玲玲,等.晚期肝癌患者行HAIC术后股动脉并发假性动脉瘤致骨筋膜室综合征的护理1例[J].介入放射学杂志,2024,33(04):459.
　CAO Jiawei,LI Huiting,XU Lingling,et al.Nursing care for osteofascial compartment syndrome caused by iatrogenic pseudoaneurysm in one patient with advanced liver cancer after receiving hepatic artery infusion chemotherapy[J].journal interventional radiology,2024,33(07):459.
[7]张岩基,王汇源,李浩,等.经导管动脉化疗栓塞和肝动脉灌注化疗治疗肝细胞癌现状和进展[J].介入放射学杂志,2024,33(09):1039.
　ZHANG Yanji,WANG Huiyuan,LI Hao,et al.Current status and progress of TACE and HAIC in the treatment of hepatocellular carcinoma[J].journal interventional radiology,2024,33(07):1039.
[8]殷梦杰,付守忠,戴锋,等.肝动脉灌注化疗联合卡瑞利珠单抗及索拉非尼治疗中晚期肝癌的疗效与安全性分析 [J].介入放射学杂志,2024,33(11):1212.
　YIN Mengjie,FU Shouzhong,DAI Feng,et al.Hepatic arterial infusion chemotherapy combined with carrelizumab and sorafenib for the treatment of advanced hepatocellular carcinoma：its clinical efficacy and safety[J].journal interventional radiology,2024,33(07):1212.
[9]杜楠,王英,李文涛.肝癌TACE还是HAIC？[J].介入放射学杂志,2024,33(12):1269.
　DU Nan,WANG Ying,LI Wentao..Treatment of hepatocellular carcinoma：TACE or HAIC？[J].journal interventional radiology,2024,33(07):1269.

备注/Memo

备注/Memo:
（收稿日期：2022- 03- 30）
（本文编辑：边 佶）
更新日期/Last Update: 2022-09-02